My CancerRisk

MyCancerRisk is an online cancer risk assessment tool, developed by Check4Cancer, for companies with more than 1,000 employees. It consists of a single questionnaire, bringing together risk assessments for each of the six most common types of cancer in the UK – bowel, breast, cervical, lung, prostate and skin cancer.

Contact us

How it works

Using your test kit is simple and secure. Here’s what to expect:

Employees complete a risk assessment questionnaire relating to the six most common cancers in the UK

Employees who are not deemed to be at ‘higher risk’ are reassured and signposted to our Cancer Education Hub for guidance on the risks, signs and symptoms of common cancers

Employees found to be at ‘higher risk’ of developing any of the six cancers can access the necessary Check4Cancer screening tests, if they meet the age and gender requirements

Any employee who undertakes a cancer screening test with an abnormal result will receive a telephone call from a Check4Cancer clinical expert to advise them to visit their GP for further advice. OR they can access Check4Cancer’s cancer diagnostic pathways for breast, skin and prostate cancers

At all times, employees have access to the Cancer Education Hub for advice and guidance

For more information on MyCancerRisk, please download the information brochure

Download the brochure

Professor Gordon Wishart

Chief Medical Officer

Professor Gordon Wishart is the founder, Chief Medical Officer and CEO of Check4Cancer, a leading early cancer detection and cancer prevention company. In 2016 Check4Cancer launched rapid access, streamlined and audited diagnostic pathways for breast and skin cancer to the insured and self-pay markets, leading to the award of “Diagnostic Provider of the Year” at the annual Health Investor Awards in 2018. In late 2017, Check4Cancer launched the first worldwide breast cancer risk test (MyBreastRisk) to combine genetic, family history and lifestyle risk factors to underpin a risk-stratified breast screening programme. As the former Director of the Cambridge Breast Unit from 2005-2010, and current Professor of Cancer Surgery at Anglia Ruskin School of Medicine since 2008, he has a strong track record in clinical research and modernisation of cancer diagnosis and treatment, with more than 100 peer-reviewed papers in scientific journals. In 2010 he led a team of clinicians and scientists that developed the PREDICT breast cancer treatment and survival model, now used worldwide.

Find out more